473
Participants
Start Date
May 18, 2016
Primary Completion Date
September 21, 2020
Study Completion Date
September 21, 2020
Peginterferon Alfa-2B
pre-received standard peginterferon alfa-2b therapy
Peginterferon Alfa-2A
pre-received standard peginterferon alfa-2a therapy
302 Military Hospital, Beijing
Beijing Ditan Hospital Capital Medical University, Beijing
Beijing Youan Hospital, Capital Medical University, Beijing
Peking University First Hospital, Beijing
Peking University People's Hospital, Beijing
Second Affiliated Hospital Chongqing Medical University, Chongqing
Southwest Hospital, Chongqing
Fuzhou Infectious Disease Hospital, Fuzhou
The First Affiliated Hospital of Xiamen University, Xiamen
Xiamen Hospital of T.C.M, Xiamen
Guangzhou Eighth People's Hospital, Guangzhou
Nanfang Hospital, Guangzhou
Beijing University Shenzhen Hospital, Shenzhen
Third Affiliated Hospital, Hebei Medical University, Shijiazhuang
Henan Provincial People's Hospital, Zhengzhou
Xiangya Hospital, Central-south University, Changsha
Xiangya Second Hospital, Central-south University, Changsha
81 Military Hospital, Nanjing
Second Hospital of Nanjing, Nanjing
First Affiliated Hospital of Nanchang University, Nanchang
Shenyang Sixth People's Hospital, Shenyang
Jinan Infectious Disease Hospital, Jinan
85 Military Hospital, Shanghai
Huashan Hospital, Shanghai
Ruijing Hospital, Shanghai
Shanghai Public Health Clinical Center, Shanghai
Tianjin Third Central Hospital, Tianjin
First Affiliated Hospital of Wenzhou Medical College, Wenzhou
Peking University First Hospital
OTHER
Xiamen Amoytop Biotech Co., Ltd.
INDUSTRY